ERBB2 and breast cancer: According to the results of the phase II PALOMA‐1 trial, palbociclib (a CDK4/6i) combined with letrozole as first‐line treatment for HR+ human epidermal growth factor receptor 2‐negative (HER2−) metastatic BC (MBC) patients almost doubled the median progression‐free survival (mPFS).6